Oct

ARDX Stock Price Ardelyx Inc Stock Quote U.S.: Nasdaq

The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer.

Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

ARDX’s beta can be found in Trading Information at the top of this page. A stock’s beta measures how closely tied its price movements have been to the performance of market cycle stages the overall market. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity.

Ardelyx has an analyst consensus of Strong Buy, with a price target consensus of $9.88, implying a 145.77% upside from current levels. In a report released on September 22, Piper Sandler also maintained a Buy rating on the stock with a $12.00 price target. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. A panel of advisers to the U.S. health regulator on Wednesday recommended the approval of Ardelyx Inc’s drug for chronic kidney disease patients on dialysis, more than a year after it was initially re…

The 84 rating InvestorsObserver gives to Ardelyx Inc (ARDX) stock puts it near the top of the Healthcare sector.
Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
Shares in Ardelyx Inc. plummeted more than 70% in after-hours trading Monday, following the biopharmaceutical company’s that the Food and Drug Administration appears unlikely to approve a drug for dialysis patients.
MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.
Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Ardelyx, Inc. is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations.

Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. ARDX, -3.17% rocketed 75.4% on heavy volume toward a 16-month high in premarket trading Thursday, after an advisory panel of the U.S. The technique has proven to be very useful for finding positive surprises.

ARDX Stock – Frequently Asked Questions

See which 3 stocks are most likely to make moves following their insider activities. The company has a one-year high of $5.13 and a one-year low of $1.10. The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

6 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Ardelyx in the last year.
This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system.
A panel of advisers to the U.S. health regulator on Wednesday recommended the approval of Ardelyx Inc’s drug for chronic kidney disease patients on dialysis, more than a year after it was initially re…
Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Shares in Ardelyx Inc. plummeted more than 70% in after-hours trading Monday, following the biopharmaceutical company’s that the Food and Drug Administration appears unlikely to approve a drug for dialysis patients.

What do These Ratings Mean?

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.

Illumina, Inc. (ILMN) Stock: Do Analysts Think You Should Sell?

View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.17% per year. These returns cover a period from January 1, 1988 through September 4, 2023.

Trading Services

According to TipRanks, Arce has an average return of 9.8% and a 42.20% success rate on recommended stocks. Ardelyx’s stock was trading at $2.85 at the beginning of the year. Since then, ARDX stock has increased by 43.2% and is now trading at $4.08. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

FDA Grants Appeal for Ardelyx’s XPHOZAH® (tenapanor)

Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat’s FREE daily newsletter. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time. This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.